Markets:

Overview

News

Currencies

International

Treasuries

Relmada Therapeutics, Inc. - Common Stock (NQ:RLMD)

4.270 -0.050 (-1.16%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Relmada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm

August 11, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says ↗

August 07, 2023

Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.

Via Benzinga

Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm

August 06, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Relmada Therapeutics: Q1 Earnings Insights ↗

May 11, 2023

Via Benzinga

Earnings Preview For Relmada Therapeutics ↗

May 10, 2023

Via Benzinga

Preview: Relmada Therapeutics's Earnings ↗

March 22, 2023

Via Benzinga

7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick ↗

July 31, 2023

For investors who choose wisely, profits in healthcare stocks can be spectacular. But the losses can also be dramatic if you choose poorly.

Via InvestorPlace

Bragar Eagel & Squire, P.C. Is Investigating Relmada, Arrival, FMC, and Viasat and Encourages Investors to Contact the Firm

July 26, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Relmada, DoubleVerify, and Castle and Encourages Investors to Contact the Firm

July 21, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm

July 16, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm

July 10, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm

July 05, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Seagate, Chegg, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm

July 01, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Relmada, DoubleVerify, Sanmina, and JinkoSolar and Encourages Investors to Contact the Firm

June 25, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Seagate, Chegg, and Relmada and Encourages Investors to Contact the Firm

June 19, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD

June 10, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Relmada, Bowlero, and Integra and Encourages Investors to Contact the Firm

June 04, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Relmada, and Sanmina and Encourages Investors to Contact the Firm

May 19, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm

May 14, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Investor Alert: Investigation Concerning Potential Securities Laws Violations ↗

May 11, 2023

San Diego, CA -- (SBWIRE) -- 05/11/2023 -- An investigation was announced for investors of Relmada Therapeutics, Inc. (NASDAQ:RLMD) shares over potential securities laws violations by Relmada...

Via SBWire

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Relmada Therapeutics, Inc. (RLMD) Investigation

May 11, 2023

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Earnings Scheduled For May 11, 2023 ↗

May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its...

Via Benzinga

RELMADA ALERT: Bragar Eagel & Squire, P.C. is Investigating Relmada Therapeutics, Inc. on Behalf of Relmada Stockholders and Encourages Investors to Contact the Firm

May 09, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

RLMD INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD

May 01, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

April 27, 2023

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

April 26, 2023

From The Schall Law Firm

Via Business Wire

Earnings Scheduled For March 23, 2023 ↗

March 23, 2023

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.

Via Benzinga

Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023 ↗

January 17, 2023

In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ: VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major...

Via Benzinga

Looking Into Relmada Therapeutics's Recent Short Interest ↗

January 03, 2023

Relmada Therapeutics's (NASDAQ:RLMD) short percent of float has fallen 13.6% since its last report. The company recently reported that it has 1.72 million shares sold short, which is 5.78% of all...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 29, 2022

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Relmada Therapeutics, Inc. - Common Stock (NQ:RLMD)

All News about Relmada Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today